-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 4D-710 in Cystic Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 4D-710 in Cystic Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 4D-710 in Cystic Fibrosis Drug Details: 4D-710 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 4D-150 in Diabetic Macular Edema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 4D-150 in Diabetic Macular Edema report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 4D-150 in Diabetic Macular Edema Drug Details: 4D-150 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 4D-125 in Retinitis Pigmentosa (Retinitis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 4D-125 in Retinitis Pigmentosa (Retinitis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 4D-125 in Retinitis Pigmentosa (Retinitis) Drug Details: 4D-125 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 4D-150 in Wet (Neovascular / Exudative) Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 4D-150 in Wet (Neovascular / Exudative) Macular Degeneration report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 4D-150 in Wet (Neovascular / Exudative) Macular Degeneration...
-
Product Insights
NewNet Present Value Model: 4D Pharma Plc’s MRx-4DP0004
Empower your strategies with our Net Present Value Model: 4D Pharma Plc's MRx-4DP0004 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: 4D Pharma Plc’s MRx-518
Empower your strategies with our Net Present Value Model: 4D Pharma Plc's MRx-518 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of 4D Molecular Therapeutics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of 4D Molecular Therapeutics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 4D-110 in Choroideremia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 4D-110 in Choroideremia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.4D-110 in ChoroideremiaDrug Details:4D-110 is under development for the treatment of choroideremia. The therapy...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALG.APV-527 in Malignant Pleural Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALG.APV-527 in Malignant Pleural Mesothelioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALG.APV-527 in Malignant Pleural Mesothelioma Drug Details: ALG.APV-527 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pepinemab in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pepinemab in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pepinemab in Non-Small Cell Lung Cancer Drug Details: Pepinemab (VX-15)...